In clinical practice, dose adjustment for SSAs is a common strategy used to manage patients with neuroendocrine tumors (NETs). The primary reason for escalating the dose is to achieve better symptom ...

Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...

Google DeepMind’s AI model generated a ‘novel hypothesis’ about how cancer cells behave, confirmed through lab experiments.

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its top-selling immunotherapy Keytruda loses patent protection. In kidney cancer, ...

Senhwa Biosciences's investigational new drug Silmitasertib (CX-4945) was recently featured in an official post by Google DeepMind, following a major breakthrough by the tech giant's biological ...

Discover Delcath’s innovative liver-targeted chemotherapy system and latest clinical data driving potential market expansion.

Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...

Bilateral Mediastinal Lymphadenectomy Is Associated With Potential Survival Advantages in Patients With Stage I Non–Small Cell Lung Cancer Who Undergo Lung Resection The AmoyDx PLC Panel, a multigene ...

The final, formatted version of the article will be published soon. Lung neuroendocrine carcinoma is a rare heterogeneous tumor with the characteristics of high invasiveness, low incidence, and poor ...

Sanofi’s $110 million bet on a radioligand seems to be paying off after the neuroendocrine tumor treatment hit the key endpoints of a phase 2 study. The asset in question, dubbed AlphaMedix, is a ...

MIT and Harvard scientists have created engineered CAR-NK cells that can hide from the immune system and more effectively destroy cancer. The cells are designed to suppress immune-rejection signals ...